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ABSTRACT Surveillance studies are required to estimate the impact of pneumococ-
cal vaccination in both children and the elderly across Europe. The World Health Or-
ganization (WHO) recommends use of enzyme immunoassays (EIAs) as standard
methods for immune surveillance of pneumococcal antibodies. However, as levels of
antibodies to multiple serotypes are monitored in thousands of samples, a need for
a less laborious and more flexible method has evolved. Fluorescent-bead-based mul-
tiplex immunoassays (MIAs) are suitable for this purpose. An increasing number of
public health and diagnostic laboratories use MIAs, although the method is not stan-
dardized and no international quality assessment scheme exists. The EU Pneumo
Multiplex Assay Consortium was initiated in 2013 to advance harmonization of MIAs
and to create an international quality assessment scheme. In a multilaboratory com-
parison organized by the consortium, agreement among nine laboratories that used
their own optimized MIA was assessed on a panel of 15 reference sera for 13 pneu-
mococcal serotypes with the new WHO standard 007sp. Agreement was assessed in
terms of assay accuracy, reproducibility, repeatability, precision, and bias. The results
indicate that the evaluated MIAs are robust and reproducible for measurement of
vaccine-induced antibody responses. However, some serotype-specific variability in
the results was observed in comparisons of polysaccharides from different sources
and of different conjugation methods, especially for serotype 4. On the basis of the
results, the consortium has contributed to the harmonization of MIA protocols to im-
prove reliability of immune surveillance of Streptococcus pneumoniae.
IMPORTANCE Serology of Streptococcus pneumoniae is challenging due to existence
of multiple clinically relevant serotypes and the introduction of multivalent vaccines
in national immunization programs. Multiplex immunoassays (MIAs) are applied as
high-throughput cost-effective methods for serosurveillance, and yet laboratories use
their own protocols. The aims of this study were to assess the agreement of results
generated by MIAs in different laboratories within the EU Pneumo Multiplex Assay
Consortium, to analyze factors contributing to differences in outcome, and to create
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a harmonized protocol. The study demonstrated good agreement of results of MIAs
performed by laboratories using controlled assays for determination of levels of
vaccine-induced pneumococcal antibodies. The EU Pneumo Multiplex Assay Consor-
tium is open to everyone working in public health services, and it aims to facilitate ef-
forts by participants to run and maintain a cost-effective, reproducible, high-quality MIA
platform.
KEYWORDS IgG antibodies, Streptococcus pneumoniae, capsular polysaccharide,
concordance, immunoserology, interlaboratory comparison, multiplex immunoassay,
quantitative methods, serosurveillance
Streptococcus pneumoniae (the pneumococcus) is an encapsulated bacterium thatcauses major infections during childhood and in the elderly, including pneumonia,
meningitis, otitis media, and sepsis (1–3). Worldwide, pneumococci are the cause of
death of more than 1 million children each year, while older adults who are 65 years
of age are disproportionately affected by pneumonia requiring hospital care (4–7). The
prevalence of pneumococcal disease varies with age but also with ethnic background,
geographical location, and time (8). A particular aspect of this bacterium is the
existence of multiple serotypes (nearly 98) that differ by the chemical composition of
their polysaccharide capsule (9, 10). About 25% of the serotypes are responsible for the
majority of pneumococcal disease in a given region (11).
Protection against pneumococcal infections is mediated by the concerted action of
antibodies and complement components opsonizing the bacteria for phagocytosis (12,
13). Serum antibodies against pneumococcal capsular polysaccharides (PPS) can pro-
tect against pneumococcal infection in a serotype-specific manner (12, 13). The licensed
pneumococcal vaccines contain a mixture of polysaccharides of different serotypes
(23-valent polysaccharide vaccine) or of polysaccharides of multiple serotypes conjugated
to protein carriers (10-valent or 13-valent conjugate vaccines). Vaccination against pneu-
mococcus has been introduced as a health care intervention in many countries (14).
Surveillance studies are required to estimate the nature and the impact of this
health care intervention for both children and the elderly across Europe. For decades,
the World Health Organization (WHO) has recommended the use of enzyme immuno-
assays (EIAs) as standard methods for immunosurveillance of anti-PPS antibodies. WHO
has established standard reference sera for use in EIA (15–17). The first standard serum,
89SF, was replaced by a new standard serum, 007sp, in 2011 by bridging to the
previous standard (17). As multiple serotypes have to be monitored and as surveillance
studies usually involve thousands of samples, it has been recognized for some time that
a less laborious and more flexible method would be preferable. Fluorescent-bead-
based multiplex immunoassays (MIAs), in combination with detailed descriptions of
chemical coupling techniques, have been developed in various laboratories and na-
tional institutions (18–20). This anti-PPS antibody screening method has been shown to
be robust, time-efficient, automatable, and economically feasible.
The recognition of pneumococcus as an important pathogen to be monitored,
along with the growing number of laboratories performing multiplex analysis of
anti-PPS antibodies, resulted in the initiation of the EU Pneumo Multiplex Assay Consortium
in 2013. The main goals of this nonprofit consortium are to share knowledge, analyze and
harmonize MIA protocols, and offer an international quality assessment scheme. Par-
ticipants include public health organizations and diagnostic laboratories as well as industry.
So far, the consortium has organized 6 annual meetings in 5 different countries.
In this paper, we describe and discuss the results of interlaboratory comparisons in
which 11 different laboratories participated using two different assay platforms, EIA and
MIA, for determination of serum anti-PPS IgG antibodies. In addition, this paper represents
the first multilaboratory study to use the new WHO standard, 007sp, for quantitation of
pneumococcal antibodies. The study was conducted to primarily assess the level of
agreement of the MIA among laboratories using their own protocols without the
introduction of any common reagents other than the serum samples to be evaluated.
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Other aims were to assess the agreement between results obtained by MIA and those
obtained by the standard WHO-approved EIA method using the new 007sp standard
and, finally, to investigate in detail possible causes of variations in outcome according
to the different sources of PPS and the different PPS conjugation methods used.
RESULTS
Interlaboratory agreement for IgG antibody concentrations. Agreement be-
tween all participating laboratories was assessed between pairs of laboratories for data
aggregated over serotypes and for serotype-specific data (Table 1). On the basis of the
aggregated data, the laboratories generally performed comparably to each other for
accuracy (Lin’s coefficient of accuracy [Ca] range, 0.90 to 0.99), precision (i.e., the
measure of how far a set of observations deviates from a straight line, quantified using
Pearson’s correlation coefficient [r]) (range, 0.84 to 0.99), and concordance (Lin’s
concordance correlation coefficient [rc], which represents a combination of Ca and r)
(range, 0.79 to 0.98). The rc values describing both accuracy and precision were 0.80
for 35/36 and 0.90 for 22/36 of the pairwise comparisons.
The degree of agreement did, however, vary by laboratory and serotype. Laboratory
I consistently overestimated the antibody concentrations for serotypes 1, 7F, 19A, and
19F and laboratory V the antibody concentrations for serotypes 1 and 5 compared to
the antibody concentrations observed in the other laboratories, as illustrated in Fig. 1.
This is also seen in the serotype-specific concordance between laboratories I and V and
the other laboratories for these serotypes; between laboratory I and the other labora-
tories, rc ranged between 0.45 and 0.77 for serotypes 1, 7F, 19A, and 19F, and between
laboratory V and the other laboratories, rc ranged between 0.58 and 0.91 for serotypes
1 and 5. In the pairwise comparisons between other laboratories, 95% yielded rc
values of 0.80 for these serotypes. For all of the other serotypes, the percentages of
pairwise laboratory-to-laboratory comparisons yielding rc values of 0.8 were 39%,
50%, 80%, 100%, 86%, 100%, 100%, and 100% for serotypes 3, 4, 6A, 6B, 9V, 14, 18C, and
23F, respectively. In line with this, the variation of the ratio of observed IgG concen-
trations to assigned values between laboratories, illustrated by the positioning of the
boxes about the dotted line in Fig. 1, was clearly dependent on the serotype, being
lowest for serotypes 14, 18C, and 23F and greatest for serotypes 1, 3, and 4 (Fig. 1).
Agreement between MIA and the assigned values for IgG concentrations. The
serotype-specific IgG antibody concentrations determined using the new 007sp stan-
dard have been assigned for a panel of 12 WHO calibration sera for 13 serotypes by EIA
(17). Box plots displaying the distribution of MIA/EIA ratios between the individual
laboratory-reported concentrations (MIA) and the assigned IgG concentrations (EIA) are
presented by serotype in Fig. 1 (laboratories I to IX). The data from most laboratories
reporting results by MIA had a negative mean bias for the majority of the serotypes
analyzed, meaning that the IgG concentrations measured by MIA are in general lower
than the assigned values. Two laboratories (I and V), however, had a substantial positive
bias for 5/13 and 2/13 serotypes. All laboratories showed only a minor bias for serotype 14.
Overall, the within-laboratory variability of the bias among the samples was higher
in MIA than in the standardized WHO EIA for all serotypes (Fig. 1). Serotypes 3, 6A, and
19A showed the highest within-laboratory variability of the bias between the IgG
concentration measured by MIA and the assigned antibody concentration (Fig. 1). For
serotypes 6A and 19A, the mean bias was negative for most laboratories, but the bias
was positive for serotype 3 in three laboratories and negative in four laboratories, and
one laboratory showed no bias. The agreement between the laboratories (X, XI, and XII)
reporting IgG concentrations determined by EIA was excellent, showing practically no
bias toward the assigned IgG concentrations. Assessing within-laboratory variation by
coefficients of variation calculated from triplicate measurements (or from duplicate
measurements for laboratory II) within each laboratory, the highest variation was seen
for serotypes 19A, 7F, and 5 (see Fig. S1 in the supplemental material).
Despite the observed negative bias, the assessed correlation between the IgG
concentrations measured by MIA in each laboratory and the assigned IgG antibody
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concentrations was good for data aggregated over serotypes (r  0.85 to 0.93, depend-
ing on laboratory) (Table 1, comparison of IgG concentrations determined by MIA) and
for the serotype-specific data (generally, r  0.85 to 0.99, excluding serotype 4 for
laboratories VI and VIII), with the exception of serotypes 3, 6A, and 19A, which showed
poorer correlation (r  0.59 to 0.88, depending on the laboratory) (Table 1, serotype-
specific comparison). Similarly, the serotype-specific analysis of concordance showed
serotype-specific differences between IgG concentrations observed by MIA and the
assigned values (Table 1, serotype-specific comparison of IgG concentrations deter-
mined by MIA). The rc values generally ranged between 0.50 and 0.95 for different
serotypes and laboratories. The lowest rc values were observed for serotypes 6A, 3, 19A,
and 4 (rc range, 0.33 to 0.77 for all laboratories, with the exception of laboratory IV for
serotype 4) and the highest for serotypes 14, 5, 18C, 19F, and 7F (rc range of 0.70 to 0.97
and rc of 0.80 for all laboratories except for laboratory V for serotype 5, laboratories
I and II for serotype 7F, and laboratory I for serotype 19F) (Table 1, serotype-specific
comparison of IgG concentrations determined by MIA).
Plotting assigned values versus outcome for each sample per serotype and per
laboratory showed that most linear regression lines appeared close to or below the line
of identity (Fig. 2). This confirms the overall negative mean bias observed already
(Fig. 1). In general, regression lines had slopes of 1 and approached the line of identity
when sera contained higher concentrations of serotype-specific antibodies. Most slopes
were categorized as representing good to excellent results. Several exceptions were
noted. Laboratories VII, VIII, and IX showed good precision for serotype 6B (r range, 0.93
to 0.94), and yet the slopes of the fitted regression line were somewhat steeper
(slope  1.5) (see Table S1 in the supplemental material), affecting the concordances (rc
FIG 1 Box plots by serotype and laboratory (I to XII) for ratios of IgG antibody concentrations (micrograms per milliliter) determined by MIA or EIA to the
assigned IgG concentrations by WHO. The hinges and the horizontal line of the box represent the 25th and 75th percentiles and the median, respectively, and
the red asterisks signify means. The size of the box, coupled with the whiskers, is a direct indicator of the within-laboratory variability of the bias corresponding
to the MIA/EIA ratios. The circles correspond to outlying assay values. The positioning of the boxes around the dotted, ideal line with a coefficient of 1 for a
given serotype across all laboratories is an indicator of the between-laboratory variability. Results from laboratories I to IX were determined by MIA and results
from laboratories X, XI, and XII by the WHO EIA. The number of samples analyzed per serotype was 13.
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range, 0.65 to 0.75) (Fig. 2 and Table 1, serotype-specific comparison of IgG concen-
trations determined by MIA). A similar combination of slope and precision was found
for laboratories II and VII regarding serotype 14, and yet their overall concordance was
good (rc values of 0.8) (Fig. 2; see also Table S2 and Table 1, serotype-specific
comparison of IgG concentrations determined by MIA). A second type of exception was
represented by regression lines above line of identity. This was observed for laboratory
I for serotypes 7F, 19A, and 19F and for laboratory V for serotype 5 (Fig. 2). The slopes
of the linear regression lines were categorized as excellent for these serotypes, with
good precision, except for 19A in the case of laboratory I (r  0.62), and yet affected the
overall concordance of the data from laboratory I for serotypes 7F, 19A, and 19F
(rc  0.72, 0.48, and 0.71, respectively) (Table 1, serotype-specific comparison of IgG
concentrations determined by MIA) (Fig. 2; see also Table S2). Other exceptions were
noted for serotypes 3, 4, and 6A. For serotype 3 and 4, regression lines were divergent
between laboratories. Concerning serotype 3, the data from laboratory VI in particular
showed poor agreement regarding the slope (slope  0.44), along with poor concor-
dance (rc  0.53) (Table 1, comparison of IgG concentration ratios determined by MIA)
(Fig. 2; see also Table S1). The data from most other laboratories had poor concor-
dances for this serotype as well (rc  0.46 to 0.77) (Table 1, serotype-specific compar-
ison of IgG concentrations determined by MIA). Only the data from laboratory III
displayed both an excellent slope and good precision (slope  1.2, rc  0.82), but the
regression line ran well above the line of identity, resulting in poor concordance
(rc  0.58) (Table 1, serotype-specific comparison of IgG concentrations determined by
MIA) (Fig. 2; see also Table S2). With serotype 4, the data from laboratories V and VI had
regression slopes that were poor (slope  0.50 for lab V and 0.37 for lab VI), together
with poor concordance in the case of laboratory VI (rc  0.55) (Table 1, serotype-specific
comparison of IgG concentrations determined by MIA) (Fig. 2; see also Table S2).
Regarding serotype 6A, there was good agreement with respect to the slopes, but the
FIG 2 Linear regression analysis panels for each serotype, with a different line for each laboratory (I to IX). In total, 13 samples with assigned concentrations
were tested: 12 sera from WHO panel B and sample 007sp. Each dot represents the mean of results of 2 or 3 measurements of each sample. The color code
of each laboratory is indicated. The line of identity is marked in black. Corresponding data representing outcomes of the linear regression analysis
(slope/confidence intervals) can be found in Table S2. Laboratory II did not submit data for serotype 3 and 19A, and laboratories I to II and VIII did not submit
data for serotype 6A. All values are in micrograms per milliliter (log transformed).
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absolute concentrations measured by each laboratory differed considerably (Table S2)
(Fig. 2), resulting in overall poor concordances (rc  0.33 to 0.64). Not all laboratories
(6/9) had this serotype included in their panel.
Analysis of variables affecting interlaboratory reproducibility. Per study design,
all participating laboratories used their own MIA, with no common reagents other than
the samples to be evaluated. For analysis of variables possibly affecting the assay
reproducibility, all laboratories were advised to report the source and batch numbers
of the pneumococcal capsular polysaccharide products and the bead conjugation
method used (see Table S1 in the supplemental material).
Comparison of polysaccharides from two different sources. In general, the
comparison of IgG antibody concentrations obtained using polysaccharides from ATCC
or SSI Diagnostica displayed good to excellent agreement (slope  0.73 to 1.15,
r  0.80 to 0.99, depending on the serotype) (Table 2), with the exception of the
serotype 3 data, which showed poor agreement (slope  0.54, r  0.66) (Table 2). Two
serotypes also stood out by having only good agreement: 6B and 19F (slope  0.73 and
0.78, r  0.88 and 0.80) (Table 2). The slope for serotype 1 was excellent; the wide
confidence intervals (0.49 to 1.30) did not, however, indicate a strong linear relation-
ship. For serotypes 1 and 6B, quantitation using polysaccharides from SSI Diagnostica
resulted in slightly higher concentrations for sera with low IgG values. However, interpre-
tation of results obtained for PPS 3, 6B, and 19F should be performed with care, as most
data points were aggregated, causing outliers to have a strong impact on the corre-
lation analysis (see Fig. S2 in the supplemental material).
Compared with the assigned values for WHO serum panel B, most polysaccharides
from either source yielded good or excellent agreement between the quantitated and
assigned values (slope  0.84 to 1.39 and 0.69 to 1.15 and r  0.75 to 0.97 and 0.78 to
0.98, respectively, for PPS originating from ATCC and SSI Diagnostica) (Table 3; see also
Fig. S2), with the exception of particular serotypes, namely, serotype 6B (ATCC and SSI
Diagnostica) (slope  0.59 and 0.34 and r  0.87 and 0.69, respectively), serotype 19A
(ATCC and SSI Diagnostica) (slope  0.89 and 0.73, respectively, and r  0.66 to 0.60 for
both), serotype 14 (ATCC) (slope  1.48 and r  0.94), and serotype 19F (SSI Diagnos-
tica) (slope  0.42 and r  0.65) (Table 3). It was striking that serotype 19A performed
well in the comparisons of PPSs from different sources (slope  0.96, r  0.97) and yet
these results clearly deviated from the assigned values (slope  0.89 and 0.73 and
r  0.66 and 0.60 for PPS from ATCC and SSI Diagnostica, respectively) (Table 3). This
may have been assay related, as the antibodies to two cross-reacting serotypes, 19A
and 19F, were quantitated simultaneously in this particular MIA setting. In EIA, in
contrast, antibodies to each serotype are quantitated in separate assays. A general
potential bias in the comparison is that all of the values assigned for WHO serum panels
A and B have been determined using polysaccharides from ATCC. Regarding repeat-
TABLE 2 Deming regression and Pearson correlation per serotype for quantitation of anti-
PPS antibodies in 13 sera from WHO panel B determined using MIA beads coated with
polysaccharides obtained from ATCC or SSI Diagnosticaa
PPS Slope LCI UCI r
1 0.99 0.49 1.30 0.87
3 0.54 0.35 0.77 0.66
4 0.99 0.85 1.12 0.93
5 1.12 0.99 1.35 0.95
6B 0.73 0.45 0.82 0.88
7F 1.06 1.01 1.12 0.99
9V 1.04 0.89 1.16 0.94
14 0.94 0.80 1.06 0.95
18C 1.15 1.03 1.27 0.97
19A 0.99 0.88 1.12 0.97
19F 0.78 0.51 0.98 0.80
23F 0.94 0.87 1.00 0.99
aLCI, lower confidence interval value; UCI, upper confidence interval value.
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ability (or precision), quantitation done with PPS from either source proved to be highly
repeatable (slope  0.87 to 1.1 and r  0.98 to 1.00, depending on the serotype)
(Fig. S3).
Comparison of conjugation methods. Two basic conjugation chemistries were
employed by the participating laboratories to conjugate PPS to carboxylated beads in
MIA: the two-step carbodiimide method involving poly-L-lysine (PLL) (18) and the
method employing 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chlo-
ride (DMTMM) (20). The conjugation chemistry used by each participating laboratory is
described in Table S1. Five laboratories used the PLL method, and four laboratories
conjugated the beads using the DMTMM method. Overall, there was more variation in
measured concentrations between PLL laboratories than between those using the
DMTMM method. This was mainly caused by higher IgG concentrations measured by
laboratories I and V for serotypes 1, 5, 7F, 19A, and 19F (Fig. 2). Furthermore, notable
variability was seen between laboratories in the data for serotypes 1, 3, and 4. This
considerable variability precludes an overall assessment of the contribution of the
conjugation method to the interlaboratory variability in this study. A higher calculated
antibody concentration (bias) was found only for serotype 4 conjugated by the PLL
method for samples with relatively low specific IgG antibody concentrations against
this serotype (slope  0.59, r  0.89) (Fig. S4).
DISCUSSION
This study evaluated the level of agreement of nine laboratories for the quantitation
of antipneumococcal capsular polysaccharide IgG antibodies by MIA. The laboratories
used their own optimized assays without any common reagents other than the serum
samples to be evaluated. The use of WHO enzyme-linked immunosorbent assay (ELISA)
calibration serum panel B with assigned values provided a common reference and
additionally enabled assessment of agreement between the data from each laboratory
and the standardized EIA. The results obtained by MIA showed remarkably high
agreement between laboratories: rc values of 0.79 for all pairwise comparisons of data
aggregated over serotypes. In general, the results obtained by MIA correlated well with
the WHO-assigned values, but a higher level of agreement was found between results
obtained by MIA in different laboratories than between the MIA and WHO-assigned
values.
The WHO recommends the use of the standardized enzyme immunoassay (EIA) as
the primary method for evaluating serological responses to pneumococcal vaccines in
infants. Alternative methods have to be bridged to this method to maintain the link
with the pivotal clinical protection studies carried out during the licensure of the first
conjugate vaccine (21). As multiple serotypes need to be monitored in surveillance
studies of pneumococcal immunity that usually involve thousands of samples, many
laboratories and national institutes have switched to high-throughput multiplex im-
TABLE 3 Slope and Pearson correlation coefficient values for calculated and WHO-
assigned values using MIA with ATCC polysaccharides or SSI Diagnostica polysaccharides
PPS
ATCC SSI Diagnostica
Slope r Slope r
1 1.39 0.96 1 0.78
3 0.98 0.75 0.78 0.85
4 0.85 0.91 0.69 0.85
5 0.97 0.97 1 0.93
6B 0.59 0.87 0.34 0.69
7F 0.90 0.96 0.96 0.98
9V 1.06 0.90 0.97 0.90
14 1.48 0.94 1.15 0.87
18C 1.03 0.94 1.08 0.89
19A 0.89 0.66 0.73 0.60
19F 0.84 0.94 0.42 0.65
23F 1.06 0.83 0.96 0.84
Pneumococcal Multiplex Immunoassay across Europe
November/December 2019 Volume 4 Issue 6 e00455-19 msphere.asm.org 9
munoassays in recent years. These assays are, however, not standardized, and no
harmonized protocol has been available. As an approach to interlaboratory quality
assurance for MIA, the interlaboratory agreement of MIA results has been assessed in
three studies previously (22–24). In the study by Whaley et al., agreement of IgG
concentrations determined by three bead-based immunoassays for WHO calibration
serum panel B was assessed. The three assays showed modest (42% to 55%) agreement
with the WHO-assigned values, with various levels of correlation between serotypes.
The results of our study are in line with the results of that previous study in that higher
interlaboratory agreement was observed between different MIAs than between MIA
and the WHO-assigned values. Additionally, the concordance level of MIAs between
laboratories in our study was good and was comparable to that reported by Whaley et
al.; in 35 of 36 (97%) pairwise comparisons, the rc value was 0.80 (22). The studies of
Zhang et al. and Daly et al. further evaluated whether the observed analytical variability
between laboratories would affect the clinical classification of patients and responses
by the use of paired clinical sera and published clinical algorithms (23, 24). They
concluded that despite substantial variation seen in absolute values of data determined
for pneumococcal antibodies, the overall classifications of the pneumococcal immune
status of patients were remarkably similar between assays. The use of the WHO ELISA
calibration sera in our study allowed us to evaluate only the absolute values of data
from pneumococcal antibodies in those samples. What is similar between the current
study and the earlier MIA comparison is that the within-laboratory variability is depen-
dent on serotype. Our study employed a more comprehensive evaluation of bead-
based pneumococcal assays than the previous studies and involved more laboratories
than previously published in the literature. Furthermore, what distinguishes our efforts
is that we have combined this with an analysis of factors that may have been responsible
for the variation observed between laboratories.
Despite the relatively good overall agreement in MIA between laboratories, the level
of agreement of MIA-assigned values varied by laboratory and serotype. Two labora-
tories (I and V) clearly deviated from the other laboratories regarding overall agreement
and variability of MIA-assigned values. This was particularly reflected in the data
determined for serotypes 1, 5, 7F, 19A, and 19F. The serotypes showing most variability
across all laboratories were serotypes 1 and 3. Nevertheless, individual laboratories all
showed good intralaboratory agreement (for the majority of laboratories and serotypes,
the coefficient of variation [CV] was 15%).
To determine which factors may be responsible for poor concordances between
laboratories, we have analyzed whether polysaccharide source and/or conjugation
procedure can be held accountable. Next to serotypes 1 and 3, considerable variation
between laboratories has been found for serotypes 4 and 6A as well. We have been able
to rule out source of polysaccharides for serotypes 1 and 4 in that respect. Regarding
serotype 1, it is still possible that differences in source and lot number contribute to the
variation, but it must be a combination of (i) factors related to differences in details
regarding conjugation procedures for polysaccharides to beads, (ii) shelf life of the
bead-polysaccharide combinations used, and (iii) differences in measurement protocols
that may have more effect on particular polysaccharides. Our results show that source
of polysaccharides does have an effect on quantitation of serotype 3-specific antibod-
ies. Even though not many laboratories used serotype 3 obtained from SSI, it will be
interest to analyze different lots available through ATCC. At the same time, the clinical
relevance of determining serotype 3-specific antibodies is being questioned (25), and
inclusion of this serotype in MIA panels may become obsolete for laboratories that
focus on protection and prevention of disease. Regarding serotype 4, this seems to be
the only serotype for which conjugation procedure has differential effects on antige-
nicity. This phenomenon was not reported in the original publication (20). It will be
worthwhile to have both conjugation procedures and shelf life of either conjugated
polysaccharide-bead combination analyzed within one laboratory. Considering sero-
type 6A, we have not analyzed source and lot number differences or effects of
differences in measurement protocols. It may be that some members within serotype
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families are more affected by differences in measurement protocols than others. The
best way to resolve this issue, and all other sources of variation that we were unable to
allocate, would be to share one batch of bead-polysaccharides and a serum panel
between laboratories and analyze outcome. This would definitely help outlier labora-
tories to resolve their potential issues.
When results obtained by MIA from each laboratory were compared to the assigned
IgG antibody values determined by the standardized WHO EIA, an overall negative bias
was observed for most serotypes in the majority of laboratories, meaning that antibody
levels generally are underestimated using MIA compared with WHO MIA. This was
particularly observed at lower (1 g/ml) IgG antibody concentrations. Exceptions
were already-mentioned serotypes 1 and 3, showing most variation and both negative
and positive bias across laboratories. Another notable exception was serotype 14, for
which only a minimal negative bias was observed in all laboratories, resulting in
excellent agreement both between laboratories and between MIA and EIA.
Several factors can contribute to the observed bias. These may include different
binding kinetics of antibodies to PPS adsorbed on solid phase or PPS on beads in liquid
phase, conformational change in PPS as a result of the covalent coupling techniques,
multiplexing itself, or differences in antigenicity of polysaccharide lots. In EIA the
antibodies bind to excess of PPS adsorbed on solid surfaces of the wells of microtiter
plates, whereas in MIA the antibodies bind to PPS on the surfaces of microspheres in
suspension. It may be that higher relative avidity is required for binding to PPS
conjugated to beads in MIA whereas high-avidity and low-avidity as well as cross-
reactive and unspecific antibodies may be able to bind in EIA. The higher density of PPS
on EIA plates than on the beads in MIA may favor the binding of both low-avidity and
high-avidity antibodies. Preference of antibodies with high avidity could be one
explanation for the negative bias of MIA results in comparison to WHO-assigned values.
One may, however, speculate that the concentration of high-avidity antibodies is of
most clinical importance upon encounter with PPS on the surface of bacteria. To
elucidate this, evaluation using well-controlled avidity assays on lower-performance
serotypes would be an important area of future research. To conclude, the negative
mean bias between the results obtained by MIA and the assigned values will probably
not have a major impact on conclusions drawn in surveillance studies assessing vaccine-
induced antibodies or in evaluation of individual vaccine responses (with a focus on fold
increase), which are the types of studies done by the laboratories within the consor-
tium. Furthermore, underestimation of antibody concentration by a given assay or for
an individual serotype may not affect clinical outcome, in contrast to overestimation of
the concentration.
Several different methods for conjugation of beads with PPS have already been
described and their comparison documented (19, 20, 26). Therefore, and since the
primary aim of this study was to evaluate the level of agreement of MIA in laboratories
using their own optimized assays without any common procedures or reagents,
comparison of conjugation methods was not within the scope of this study. Due to
several other variables affecting MIA performance, e.g., the use of different sources and
batches of PPS in different laboratories and of different combinations of serotypes in
assays, interpretation of results of conjugation method comparisons should be done
with care. In general, comparable results were obtained regardless of conjugation
method, with the exception of the results obtained with serotype 4.
Regarding polysaccharide lots, a high degree of agreement was found in IgG concen-
trations between PPS batches obtained from either ATCC or SSI Diagnostica, specifically,
for serotypes 5, 7F, 18C, and 23F. In contrast, lower agreement was found for serotypes
3, 6B, and 19F. Understanding the effects of different polysaccharide batches may have
in MIA will require extensive biochemical comparisons. Differential effects of purifica-
tion procedures on labile groups attached to polysaccharides, such as O-acetylation,
have been described previously (9). Such labile groups can be important for confor-
mation and antigenicity of polysaccharides (9). Why a relatively simple polysaccharide
such as a serotype 3 polysaccharide shows considerable heterogeneity between man-
Pneumococcal Multiplex Immunoassay across Europe
November/December 2019 Volume 4 Issue 6 e00455-19 msphere.asm.org 11
ufacturers, or between laboratories, for that matter, is not clear, and resolution of that
issue would require additional biochemical and structural analysis. Because PPS 3 has
a relatively simple configuration (9), the likelihood of loss of important epitopes in the
conjugation procedure is increased, which may introduce more variability. Further-
more, various PPS batches obtained from different manufacturers have been previously
compared using the EIA methodology (27, 28). Remarkable differences in antibody
measurements using preparations from different manufacturers were reported, which
eventually led to the inclusion of an irrelevant PPS 22F absorption step in EIA and later
in MIA (29).
Our study had some limitations. The serum panel used for assessing agreement
between laboratories and methods consisted solely of postvaccination adult sera with
relatively high antipneumococcal IgG concentrations, and the number of samples
assessed by serotype was relatively low. Hence, assessments of fold changes in anti-
body levels and, furthermore, clinical classification of responses were not possible with
this sample panel. However, the ranges of the IgG concentrations in the WHO serum
panel covered well the expected range in samples during immunosurveillance (30),
except for serotype 14, for which assay comparability could be assessed only at IgG
concentrations above 1.49 g/ml.
The results of this study suggest that the bead-based multiplex immunoassays
evaluated are robust and reproducible for the determination of vaccine-induced pneu-
mococcal antibodies for immunosurveillance when performed by laboratories using
controlled assays. However, we recognize that the assay did not perform optimally for
all serotypes in all laboratories. On the basis of the results of this study and recent work
of the consortium, a harmonized protocol for determination of pneumococcal antibod-
ies by MIA has been created by the consortium. Individual laboratories have the
opportunity to compare and improve performance regarding overall outcome, al-
though it is not always evident what factor is responsible for a poorer outcome of a
limited number of polysaccharides while most other serotypes perform well in the
interlaboratory comparison.
On the basis of the results of this interlaboratory study, an important recommen-
dation from the consortium for the PPS manufacturers is to supply more-detailed
information regarding the composition and purity of the PPSs. The consortium and the
PPS manufacturers could collaborate to establish methods to improve characterization
and quality of PPS used in clinical diagnostic laboratories. Other future focus points
of the consortium are to further harmonize the MIA protocols in order to improve
accuracy and reproducibility on a Europe-wide scale. This would include efforts to
create a shared platform for production of beads and to establish an expiration date for
each bead-polysaccharide conjugate, particularly for PPS conjugated using DMTMM
methodology. Furthermore, any laboratory using new platforms that allow multiplex
analysis of anti-PPS antibodies would be invited to join the consortium, participate in
the development of the quality assessment scheme, discuss outcome, and further
improve on protocols. A better understanding of variables affecting variation between
laboratories is likely to improve concordance with the WHO EIA. Collaboration will aim at
improving the reliability of pan-European immunosurveillance of Streptococcus pneu-
moniae.
An important area of future evaluation by the pneumococcal assay scientific community
will be the emerging replacement serotypes. The flexibility of MIA allows additional
serotypes to be incorporated easily in a single assay as long as antibody values are
assigned with respect to the reference serum. Future testing demands can be met by
fully utilizing the capacity of the MIA-based techniques.
MATERIALS AND METHODS
Study design. Eleven participating laboratories (listed in Table 4) measured IgG pneumococcal
antibody concentrations in a panel of 15 samples distributed by Public Health England (PHE), United
Kingdom. The panel consisted of 12 sera of pneumococcal ELISA calibration serum panel B for use with
the 007sp standard (17), 007sp standard, and two in-house control sera from PHE. The IgG concentrations
in calibration serum panel B ranged between 0.19 and 6.93, 0.09 and 1.65, 0.16 and 6.68, 0.37 and 63.31,
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0.34 and 4.93, 0.21 and 9.81, 0.31 and 30.79, 0.27 and 5.50, 1.49 and 109.5, 0.23 and 14.14, 0.36 and 41.86,
0.44 and 10.73, and 0.15 to 24.66 g/ml for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F,
respectively. The samples were relabeled before distribution by PHE, and the assigned antibody
concentrations of the samples were handled by all laboratories in a blind manner. All laboratories
quantified the sera against the presently available 007sp standard. The sera were analyzed for IgG against
the different PPSs in two or three independent runs, depending on the laboratory. The number of
serotypes assayed ranged from 7 to 23 depending on the laboratory. Either of two assay platforms, MIA
or the WHO EIA, was used (for details, see Table 4 and Table S1 in the supplemental material). The
assessment of agreement between laboratories and assay platforms was restricted to results measured
using 007sp as the standard and to laboratories that reported results for at least 10 serotypes assayed
in at least two independent runs.
Multiplex immunoassay. The protocols used by each laboratory and the harmonized version are
summarized in Table S1.
Enzyme immunoassay. The WHO EIAs were essentially performed as described previously by
Wernette et al. (31).
PPS source comparison. The serotype-specific anti-PPS IgG antibodies were measured in human
serum samples utilizing PPS from two different manufacturers, namely, American Type Culture Collec-
tion, Manassas, VA, USA (ATCC), and SSI Diagnostica, Hilleroed, Denmark (see Text S1). PPSs were
conjugated to beads by the use of the two-step carbodiimide reaction as described previously by Lal et
al. (18). MIA was performed according to the protocol of laboratory I (see Table S1), and all samples were
analyzed in duplicate. The human serum samples included 97 routine diagnostic serum samples from SSI
(unknown donors, unknown vaccination status) and 24 serum samples obtained from WHO; 12 samples
from pneumococcal ELISA calibration serum panel A (for use with 89SF), and 12 samples from panel B
(for use with 007sp). The panel A samples have assigned values for IgG antibodies against seven
serotypes included in this study (4, 6B, 9V, 14, 18C, 19F, and 23F), whereas the panel B samples have
assigned values for IgG antibodies against 12 serotypes evaluated in this study (1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F, and 23F) (17). IgG concentration data (given as micrograms per milliliter) were log
transformed for statistical analysis.
Conjugation method comparison. The following two basic conjugation chemistries were employed to
conjugate PPSs to carboxylated beads for MIA: the two-step carbodiimide method involving poly-L-lysine
(PLL) (18, 19) and the method employing 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride
(DMTMM) (20). The conjugation chemistry used by each participating laboratory is described in Table S1.
Statistical analysis. All IgG antibody concentrations were expressed as micrograms per milliliter.
Each laboratory-measured concentration was calculated as the geometric mean of the concentrations
determined in two or three independent runs of each sample in each laboratory. All antibody concen-
trations were log transformed prior to analysis. Accuracy is defined as the closeness of a laboratory-
measured value to the assigned value and is measured using Lin’s coefficient of accuracy (Ca). Precision
is a measure of how far a set of observations deviates from a straight line and is quantified using
Pearson’s correlation coefficient (r). Lin’s concordance correlation coefficient (rc), which represents a
combination of Ca and r, was employed to form a single statistic describing both accuracy and precision.
Bias is a measure of the directional error of the laboratory-measured value with respect to the assigned
value. Within-laboratory variability was assessed by percent coefficient of variation (CV%) of results from
the two or three independent measurements. The criterion for acceptable variability was set to a CV
value of 20%. The parameters chosen and criteria for good agreement between bead-based assays
(rc  0.80) were based on work by Whaley et al. (22). In the analyses of PPS sources and conjugation
methods, the antibody results were compared by the use of Deming regression. The results of the
regression analyses were divided into categories according to the following criteria: excellent agreement,
1.2  slope  0.8; good agreement, 1.4  slope  0.6; poor agreement, 1.4  slope  0.6.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00455-19.
TABLE 4 Participating laboratories and assay platformsa
Institution Assay platform(s) Reference(s)
Institute of Child Health (UCL), London, United Kingdom WHO EIA 31
National Institute for Health and Welfare (THL), Helsinki, Finland MIA 20
National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands MIA 18, 28
Norwegian Institute of Public Health (NIPH), Oslo, Norway MIA 20
Public Health Agency of Sweden, Stockholm, Sweden MIA 20
Public Health England (PHE), Manchester, United Kingdom MIA 18
Quest Diagnostics, Infectious Disease, San Juan Capistrano, CA, USA MIA 20
Reinier HAGA MDC, Delft, The Netherlands WHO EIA, MIA 18, 31, 32
St Antonius Hospital, Nieuwegein, The Netherlands MIA 18, 31, 32
Statens Serum Institut (SSI), Copenhagen, Denmark MIA 18
University of Alabama, Birmingham, AL, USA WHO EIA 31
aThe laboratories are listed alphabetically, and this order is not associated with designations I to XII.
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TEXT S1, DOCX file, 0.01 MB.
FIG S1, TIF file, 0.1 MB.
FIG S2, TIF file, 1.9 MB.
FIG S3, TIF file, 1.8 MB.
FIG S4, TIF file, 0.2 MB.
TABLE S1, DOCX file, 0.05 MB.
TABLE S2, DOCX file, 0.1 MB.
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